Page last updated: 2024-09-05

erlotinib hydrochloride and Allergy, Drug

erlotinib hydrochloride has been researched along with Allergy, Drug in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Grazioso Russi, E; Numico, G; Silvestris, N	1
Gaya, A; Khorshid, M; Plowman, PN; Walther, JC	1

Reviews

1 review(s) available for erlotinib hydrochloride and Allergy, Drug

Article	Year
Advances in EGFR-directed therapy in head and neck cancer. Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis	2011

Article

Year

Advances in EGFR-directed therapy in head and neck cancer.

Frontiers in bioscience (Scholar edition), 2011, 01-01, Volume: 3, Issue:2

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis

2011

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Allergy, Drug

Article	Year
Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash. Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:8 Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Skin Diseases, Vesiculobullous	2006

Article

Year

Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.

Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:8

Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Skin Diseases, Vesiculobullous

2006